---
layout: post
title: "Good Abbreviated New Drug Applications Submission Practices; Guidance for Industry; Availability"
date: 2026-02-05 18:57:51 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2022-01580
original_published: 2022-01-27 00:00:00 +0000
significance: 8.00
---

# Good Abbreviated New Drug Applications Submission Practices; Guidance for Industry; Availability

**Published:** February 05, 2026 18:57 UTC
**Source:** Federal Register
**Original Published:** January 27, 2022 00:00 UTC
**Document Number:** 2022-01580

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled "Good ANDA Submission Practices." This guidance is intended to assist applicants preparing to submit to FDA abbreviated new drug applications (ANDAs). This guidance highlights common, recurring deficiencies that may lead to a delay in the approval of an ANDA. It also makes recommendations to applicants on how to avoid these deficiencies with the goal of minimizing the number of review cycles necessary for approval. This guidance finalizes the draft guidance entitled "Good ANDA Submission Practices" issued on January 4, 2018.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2022/01/27/2022-01580/good-abbreviated-new-drug-applications-submission-practices-guidance-for-industry-availability)
- API: https://www.federalregister.gov/api/v1/documents/2022-01580

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
